Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized adaptive study of defibrotide for prevention of hepatic veno-occlusive disease after HSCT
MOH_2017-03-13_000224Phase 3Not yet recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2016
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatic veno-occlusive disease (HVOD) comparing Defibrotide + best supportive care with Best supportive care (2 arms). Primary endpoint: VOD-free survival through Day +30 after HSCT. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on MOH_2017-03-13_000224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-13_000224.